



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	134.23
Trade Time:	4:15 PM ET Jun 28, 2017
Change:	3.38 (2.583%)
Day Range	130.39 - 134.66
52-Week Range	96.93 - 135.18
Volume	5,245,131

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup> and ISTODAX<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 22, 2017*

[Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign](#)

*Jun 19, 2017*

[Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017](#)

*Jun 17, 2017*

[Updated Data from Phase IIIb MAGNIFY Study of REVLIMID \(lenalidomide\) and Rituximab Combination \(R2\) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma](#)

*Jun 14, 2017*

[Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus](#)

*Jun 6, 2017*

[Updated Data from Phase 1 Trial of Oral IDHIFA<sup>®</sup> \(enasidenib\) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation](#)

## Financials [\[ View all \]](#)

*Feb 10, 2017*

[Annual Report \(10-K\)](#)

*Apr 27, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Apr 27, 2017*

[Quarterly Report \(10-Q\)](#)

*Oct 27, 2016*

[Quarterly Report \(10-Q\)](#)

*Jul 28, 2016*

[Quarterly Report \(10-Q\)](#)

